Meta-analysis of the prevention of nausea and vomiting associated with highly emetogenic chemotherapy regimens using aprepitant and fosaprepitant
Objective To systematically evaluate the efficacy and safety of aprepitant and fosaprepitant in the prevention of highly emetogenic chemotherapy(HEC)related nausea and vomiting.Methods Randomized controlled trials were searched by computer from Embase,PubMed,Cochrane Library,CNKI,Wanfang,and VIP databases on the efficacy and safety of fosaprepitant and aprepitant in the prevention of HEC related nausea and vomiting,with the retrieval time limit from the establishment of the database until December 2022.After independently screening and evaluating the risk of bias,two investigators used RevMan 5.4 software for Meta-analysis.Results Finally,7 articles were included,involving 4932 patients.The Meta-analysis results showed that there was no significant difference in total complete remission rate of vomiting in the observation period and delay period,total complete control rate of vomiting in the observation period,acute period,and delay period,salvage treatment proportion,and incidence of adverse reactions between fosaprepitant and aprepitant(P>0.05).The complete remission rate of vomiting in the acute period of fosaprepitant was higher than that of aprepitant(RR=1.02,95％CI[1.00,1.04],P<0.05).Conclusion Fosaprepitant and aprepitant have equivalent preventive effects on nausea and vomiting associated with HEC,and patients have good tolerance.Fosaprepitant is superior to aprepitant in preventing vomiting in the acute period.
Nausea and vomiting associated with chemotherapy drugsHighly emetogenic chemotherapyAprepitantFosaprepitantMeta-analysis
万方数据
维普
